Novo Nordisk's H1 sales increased by 24% in Danish kroner

For the 2024 outlook, sales growth is now expected to be 22-28% at CER

Metropolis Healthcare posts Q1 FY25 at Rs. 38.1 Cr

Revenue from operations stood at Rs. 313.4 crore during Q1 FY25

Merck inks MoU with Aragen to facilitate supply of equipment and technologies for mAb

This accelerates the clinical-to-commercial process timeline and enables customers to develop the right molecule

Zydus Lifesciences Q1 FY25 revenue up 21% YoY to reach Rs. 6,207.5 Cr

Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues

HealthCare Global Enterprises posts Q1 FY25 PAT higher at Rs. 12.1 Cr

Our centers are performing as expected or even better

Jan Aushadhi Kendras have sold Rs. 5,600 Cr medicines over last 10 years

The sales of medicines and other items sold through Jan Aushadhi Kendras have increased from Rs. 7.29 crore in 2014 to Rs. 1,470 crore by July 2024

IOL Chemicals and Pharmaceuticals posts Q1 FY25 PAT at Rs. 29.7 Cr

The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24

AstraZeneca Pharma India achieves 31% revenue growth in Q1 FY25

The results are an outcome of the company's focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years

Bio-economy is going to spearhead India’s future growth story: Dr. Jitendra Singh

Lonza upgrades clinical manufacturing services at Bend site to include bottling and labeling capabilities

Lonza Bend (US) upgrades capabilities in early phase clinical manufacturing services with the addition of bottling and labeling equipment